Nasal Drops Show Promise in Combatting Glioblastoma

Researchers at Washington University have developed a novel treatment for glioblastoma, one of the deadliest forms of brain cancer, using nasal drops that can travel along the nerves of the nose into the central nervous system. Preliminary tests indicate that this method effectively delivers medication to the brain, providing protection against these typically fatal tumors in mice. Neurosurgeon Alexander Stegh emphasized the significance of this approach, stating, "This is an approach that offers hope for safer, more effective treatments for glioblastoma and potentially other immune treatment-resistant cancers."

ScienceAlert

Glioblastoma is characterized by its aggressive nature and difficulty in early detection. The tumors not only impair brain functions by causing swelling in surrounding tissues but also deactivate the body's immune response, complicating treatment efforts. Traditional therapies often struggle to reach these tumors due to their location within the brain and central nervous system.

ScienceAlert

The research team, led by neuroscientist Akanksha Mahajan, aimed to simplify drug delivery to glioblastoma tumors. They utilized nanotechnology to create spherical nucleic acids that encapsulate STING-activating molecules, enhancing their stability and effectiveness. This innovative delivery system minimizes the need for invasive procedures, which are often burdensome for patients already facing severe illness. Mahajan noted, "We really wanted to minimize patients having to go through that when they are already ill."

ScienceAlert

In their experiments, the researchers found that the gold-mounted genetic instructions successfully activated the STING pathway, inhibiting tumor growth in mice. When combined with additional drugs aimed at boosting immunity, the nasal drops induced long-term immunity against glioblastoma, marking a significant advancement in treatment strategies.

ScienceAlert

While the results are promising, the researchers caution that further studies are necessary before moving to human clinical trials. The team acknowledges that glioblastoma cells may develop ways to evade the STING pathway, necessitating a multifaceted approach to treatment. Stegh highlighted the personal motivation behind this research, recalling the impact of his grandmother's battle with metastatic brain tumors, which inspired him to pursue advancements in understanding and treating brain cancer.

ScienceAlert

The research findings were published in the Proceedings of the National Academy of Sciences (PNAS), and the team remains optimistic about the potential of this treatment. However, they stress the importance of continued research to ensure the efficacy and safety of this innovative approach.

ScienceAlert

• "This is an approach that offers hope for safer, more effective treatments for glioblastoma and potentially other immune treatment-resistant cancers." — Alexander Stegh, Neurosurgeon

ScienceAlert

• "We really wanted to minimize patients having to go through that when they are already ill." — Akanksha Mahajan, Neuroscientist

ScienceAlert

• "When my grandmother developed metastatic brain tumors after being diagnosed with end-stage breast cancer, I experienced the vicious toll the disease had on her and everyone around her." — Alexander Stegh, Neurosurgeon

ScienceAlert

This research represents a critical step toward developing more effective treatments for glioblastoma, with the potential to change the landscape of cancer immunotherapy.

ScienceAlert